

DETAILS OF FAMILIARISATION PROGRAMMES IMPARTED TO INDEPENDENT DIRECTORS

- In-depth presentation on business model of the Company including industry structure, outlook, risks and concerns are made to all the Directors from time to time as part of board meeting discussion.
- Updates on various statutory and regulatory changes are also included as part of board discussion.
- The details of other programs organized for directors including independent directors are as follows:

| Date of Programs | Details of Program |
|---------------------------------|---|
| 30 th May, 2016 | <ol style="list-style-type: none"> 1. Recent regulatory changes concerning the pharma industry in the domestic market: <ol style="list-style-type: none"> a. Ban on the sale of certain fixed dose combinations and current status of implementation thereof; and b. Recent changes in the pricing of the scheduled formulations covered under the price control regime. 2. Steps initiated by the Company with regard to regulatory challenges faced due to US FDA import alert / warning letter on few of the Company's manufacturing sites. |
| 11 th August, 2016 | <ol style="list-style-type: none"> 1. Steps taken by the Company to mitigate regulatory challenges faced by generics manufacturers. 2. Update on journey initiated in association with Dupont on safety culture at all the manufacturing sites of the Company. 3. Brief presentation by Statutory Auditors / CFO on implementation of Indian Accounting Standards. |
| 11 th November, 2016 | <ol style="list-style-type: none"> 1. Recent regulatory changes concerning the pharma industry in the domestic market: <ol style="list-style-type: none"> a. Notices being issued by Central Government for new round of ban on the sale of certain fixed dose combinations; and b. Recent changes in the pricing of the scheduled formulations covered under the price control regime. 2. Steps continued to be undertaken by the Company with regard to regulatory challenges faced due to US FDA import alert / warning letter on few of the Company's manufacturing sites. 3. A brief presentation by Statutory Auditors / CFO on Indian Accounting Standards Requirements. |
| 10 th February, 2017 | <ol style="list-style-type: none"> 4. Presentation by CFO on GST and the steps taken by the Company for its implementation. |

| Attendance of Independent Directors in the above programs | | | | |
|--|---------------------------------|--------------------------------------|--|--------------------------------------|
| Name of Independent Director | No. of programs attended | | No. of hours spent in the programs attended | |
| | 2016-17 | On cumulative basis till date | 2016-17 | On cumulative basis till date |
| Mr. Babulal Jain | 4 | 9 | 4 | 9 |
| Mr. Anand T. Kusre | 4 | 9 | 4 | 9 |
| Mr. Dev Parkash Yadava | 4 | 9 | 4 | 9 |
| Dr. Ramakanta M. Panda | 3 | 8 | 3 | 8 |
| Dr. (Ms.)Manisha Premnath | 3 | 7 | 3 | 7 |